Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion
The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes
We haven't written up this one. Business Standard IN has the full story — the link below goes straight to it.